AMG 334
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rosacea
Conditions
Rosacea
Trial Timeline
Jun 9, 2020 → Aug 1, 2021
NCT ID
NCT04419259About AMG 334
AMG 334 is a phase 2 stage product being developed by Novartis for Rosacea. The current trial status is unknown. This product is registered under clinical trial identifier NCT04419259. Target conditions include Rosacea.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04419259 | Phase 2 | UNKNOWN |
| NCT03974360 | Phase 2 | Completed |
Competing Products
20 competing products in Rosacea